Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2020; 12(4): 383-393
Published online Apr 15, 2020. doi: 10.4251/wjgo.v12.i4.383
Published online Apr 15, 2020. doi: 10.4251/wjgo.v12.i4.383
Potential microRNA panel for the diagnosis and prediction of overall survival of hepatocellular carcinoma with hepatitis B virus infection
Qi Zhang, Wen-Yue Song, Yong-Bo Song, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning Province, China
Hai-Feng Xu, Peng-Jun Zhang, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital and Institute, Beijing 100142, China
Author contributions: Zhang Q, Xu HF, Song YB and Zhang PJ designed the study; Zhang Q performed the research; Xu HF and Song WY analyzed the data; Zhang Q and Xu HF wrote the paper; Song YB and Zhang PJ revised the manuscript for final submission; Zhang Q and Xu HF contributed equally to this study; Song YB and Zhang PJ are the co-corresponding authors.
Supported by the National Key R&D Program of China , No. 2016YFC0106604 .
Institutional review board statement: The study was reviewed and approved by the Peking University Cancer Hospital & Institute review board. All study participants or their legal guardian provided written informed consent prior to study enrollment.
Conflict-of-interest statement: We declare that we have no financial or personal relationships with other individuals or organizations that can inappropriately influence our work and that there is no professional or other personal interest of any nature in any product, service and/or company that could be construed as influencing the position presented in or the review of the manuscript.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Yong-Bo Song, PharmD, Associate Professor, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenhe District, Shenyang 110016, Liaoning Province, China. songyongbo@syphu.edu.cn
Received: December 22, 2019
Peer-review started: December 22, 2019
First decision: January 19, 2020
Revised: February 6, 2020
Accepted: March 23, 2020
Article in press: March 23, 2020
Published online: April 15, 2020
Peer-review started: December 22, 2019
First decision: January 19, 2020
Revised: February 6, 2020
Accepted: March 23, 2020
Article in press: March 23, 2020
Published online: April 15, 2020
Core Tip
Core tip: Abnormal expression of microRNAs (miRNAs) may lead to an abnormal physiological state and disease, such as, kinds of cancers. We detect the levels of miR-375, miR-122, miR-143 and miR-224. By combination of the miRNA panels, the area under the curves of the receiver-operating-characteristic curve was 0.991. In addition, the four miRNAs (miR-375, miR-122, miR-143 and miR-224) may be helpful for early detection and prognosis of hepatocellular carcinoma.